Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622103 | 0.85 | MYC (0.42) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL497718 | 0.81 | NR4A2 (0.63) | PRPS1NR4A2KMT2AMEN1L3MBTL1 | |
| SCHEMBL26613882 | 0.81 | NLRP3 (0.40) | ALDH1A1LMNA | |
| SCHEMBL30633673 | 0.81 | NLRP3 (0.40) | ALDH1A1LMNA | |
| SCHEMBL2591110 | 0.81 | MAPT (0.40) | NR4A2KMT2AMEN1L3MBTL1CHEK1 | |
| SCHEMBL22790243 | 0.80 | PRPS1 (0.43) | PRPS1NR4A2KMT2AMEN1L3MBTL1 | |
| SCHEMBL22790247 | 0.80 | KMT2A (0.44) | PRPS1NR4A2KMT2AMEN1L3MBTL1 | |
| SCHEMBL2772955 | 0.80 | NR4A2 (0.47) | NR4A2KMT2AMEN1CA12CA1 | |
| SCHEMBL2434968 | 0.80 | NR4A2 (0.65) | NR4A2KMT2AMEN1L3MBTL1CA12 | |
| SCHEMBL2642669 | 0.80 | IDO1 (0.46) | KMT2AMEN1ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| CN-101374834-B | Compounds and methods for modulating FXR | ELI LILLY AND CO. (US) | 2011-12-14 | — | — | CN | disclosed |
| CN-101448791-B | Fxr agonists | LILLY CO ELI | 2011-11-16 | — | — | CN | disclosed |
| US-7928264-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7863302-B2 | Compounds and methods for modulating FX-receptors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| CN-101039902-B | Aminoalcohol derivatives | ASTELLAS PHARMA INC | 2010-11-10 | — | — | CN | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| CN-101448798-A | Compounds and methods for modulating FXR | LILLY CO ELI (US) | 2009-06-03 | — | — | CN | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| CN-101374834-A | Compounds and methods for modulating FXR | LILLY CO ELI (US) | 2009-02-25 | — | — | CN | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| US-20080039506-A1 | Aminoalcohol Derivatives | ASTELLAS PHARMA INC. (JP) | 2008-02-14 | — | — | US | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| CN-101039902-A | Aminoalcohol derivatives | ASTELLAS PHARMA INC (JP) | 2007-09-19 | — | — | CN | disclosed |
| EP-1791811-A1 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006033446-A1 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | PRPS1 2300/4885NR4A2 1079/4885KMT2A 3741/4885 |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | PRPS1 3642/4885NR4A2 529/4885KMT2A 4324/4885 |
| US-20080039506-A1 | Aminoalcohol Derivatives | HRH4, HRH2, CBR3 | PRPS1 2212/4885NR4A2 1493/4885KMT2A 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.